Highly Enantioselective Catalysis by Enzyme Encapsulated in Metal Azolate Frameworks with Micelle-Controlled Pore Sizes

• Published in: ACS central science Vol. 10; no. 2; pp. 358 - 366
• Main Authors: Ren, Hao, Yuan, Jian, Li, Yi-Ming, Li, Wen-Jing, Guo, Yi-Hang, Zhang, Yi-Bo, Wang, Bing-Hao, Ma, Kaili, Peng, Lu, Hu, Guping, Wang, Wen-Qi, He, Hailong, Chou, Lien-Yang, Zeng, Ming-Hua, Zhang, Yue-Biao, Cheng, Lin
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 28.02.2024
• ISSN: 2374-7943; 2374-7951
• DOI: 10.1021/acscentsci.3c01432

Encapsulating enzymes within metal–organic frameworks has enhanced their structural stability and interface tunability for catalysis. However, the small apertures of the frameworks restrict their effectiveness to small organic molecules. Herein, we present a green strategy directed by visible linker micelles for the aqueous synthesis of MAF-6 that enables enzymes for the catalytic asymmetric synthesis of chiral molecules. Due to the large pore aperture (7.6 Å), double the aperture size of benchmark ZIF-8 (3.4 Å), MAF-6 allows encapsulated enzyme BCL to access larger substrates and do so faster. Through the optimization of surfactants’ effect during synthesis, BCL@MAF-6-SDS (SDS = sodium dodecyl sulfate) displayed a catalytic efficiency (K cat/K m) that was 420 times greater than that of BCL@ZIF-8. This biocomposite efficiently catalyzed the synthesis of drug precursor molecules with 94–99% enantioselectivity and nearly quantitative yields. These findings represent a deeper understanding of de novo synthetic encapsulation of enzyme in MOFs, thereby unfolding the great potential of enzyme@MAF catalysts for asymmetric synthesis of organics and pharmaceuticals.